Gestational Trophoblastic Disease Market: Global Industry Forecast (2022-2027) by Type, Treatment, End-User, and Region

Gestational Trophoblastic Disease Market size was valued at US$ 2.12 Bn. in 2021 and the total Gestational Trophoblastic Disease revenue is expected to grow at 4.1% through 2022 to 2027, reaching nearly US$ 2.7 Bn.

Gestational Trophoblastic Disease Market Overview:

The term Gestational Trophoblastic Disease (GTD) refers to a category of uncommon cancers that appear during the first trimester of pregnancy. A woman's body prepares for pregnancy after conception by forming a layer of cells called the trophoblast around the freshly fertilized egg or embryo. The trophoblast aids the embryo's implantation into the uterus. These cells also make up a major portion of the tissue that makes up the placenta, which is the organ that feeds a growing child. In GTD, aberrant alterations in the trophoblast cells lead to the formation of tumors. GTD is more likely to develop if the woman is under 22 years old or over 36 years old and if she has had previous GTD. Molar pregnancies affect women of all ages, but women under the age of 17 and over the age of 40 have a higher risk of developing one. Being of Asian ancestry is a significant risk factor. Irregular conceptions with increased placental maturation are known as hydatidiform moles. Gestational Trophoblastic Disease Market To know about the Research Methodology :- Request Free Sample Report In this report, the Gestational Trophoblastic Disease market's growth reasons, as well as the market's many segments (Type, Treatment, End-User, and Region), are discussed. Data has been given by market players, regions, and specific requirements. This market report includes a comprehensive overview of all the significant improvements that are presently prevailing in all market segments. Key data analysis is presented in the form of statistics, infographics, and presentations. The study discusses the Gestational Trophoblastic Disease market's Drivers, Restraints, Opportunities, and Challenges. The report helps to assess the market growth drivers and determines how to use these drivers as a tool. The report also helps to rectify and resolve issues related to the global Gestational Trophoblastic Disease market situation.

Gestational Trophoblastic Disease Market Dynamics:

• The primary driver of the market is the rising patient preference for no-invasive procedures. Because of the benefits given by these techniques over standard treatment processes, the demand for minimally invasive procedures has increased significantly in recent years. Fewer operating problems, shorter hospitalization, less discomfort, smaller and more aesthetic incisions, decreased risk of infection, reduced post-surgical care, and faster recovery are all advantages of minimally invasive treatments. Advanced techniques are used in minimally invasive treatments to detect and treat a variety of disorders, including cancer. • A major driver of the market is the shortage of skilled physicians and technicians. The interventional oncology industry is undergoing constant technical improvements to improve the accuracy and specificity of equipment and methods. However, GTD interventional oncology is a procedure in which only full-time professionals can reach and maintain excellent standards. As a result, the interventional oncology industry is projected to be hampered by a scarcity of well-trained and qualified radiologists and oncologists. In the United States, for example, a shortfall of more than 2900 medical oncologists is projected by 2027. • The key opportunity in the market is that emerging economies offer promising potential in the oncology healthcare sector. In numerous growing nations, e.g. Brazil, and Mexico, rapid economic growth and rising health expenditures are projected to enhance access to high-quality healthcare. This is viewed as a favorable sign for interventional oncology growth. As the prevalence of cancer rises in these nations, the need for different interventional oncology products and treatments rises.

Gestational Trophoblastic Disease Market Segment Analysis:

By Treatment, the radiation therapy segment is expected to grow at a CAGR of 6.8% in the previously mentioned forecast period. The radiation industry has undergone major technological improvements in the recent decade. These breakthroughs have aided in the creation of more efficacious, low-cost, and simple-to-use radiotherapy devices with enhanced and accurate radiation dose administration for tumor progression targeting effectiveness. High uniformity of radiation to the target (with little contact to healthy tissue) and dosage increment with enhanced tumor control has been possible by the development from 2D to 3D conventional radiation therapy with real-time monitoring. Products that give these advantages are projected to have a very strong growth potential in a short period, particularly in established markets where technologically sophisticated products are widely adopted. Gestational Trophoblastic Disease Market The size of radiotherapy equipment is greater, and they require a lot of areas to be installed. As a result, one of the key problems limiting the implementation of radiotherapy systems in emerging and developing nations is a lack of suitable healthcare systems due to restricted healthcare spending. Only a small number of healthcare organizations in undeveloped and emerging nations are now equipped to treat cancer using modern radiation devices. As a result, despite considerable demand, the number of radiation operations is being limited.

Gestational Trophoblastic Disease Market Regional Insights:

The market is predicted to grow because of an increase in cancer factors impacting this ailment spectrum. High maternal age, the growth in abnormal pregnancies, and heavy smoking are all risk factors. Cigarette smoking kills an estimated 200,000 women in the United States per year, per the American Lung Association. Furthermore, the increase in oncology-related advancements is expected to contribute considerably to the market's growth in the region. One of the biggest challenges in providing treatment for patients with treatable tumors in countries like Africa is a lack of medical doctors, radiologists, and other cancer-related healthcare professionals. Similarly, oncologists, radiotherapists, and surgical oncologists are in low supply in India. Only one oncologist handles every 2,200 cancer patients in the country, even though there are over 1.5 million cancer patients. Despite the availability of a large primary patient population, the scarcity of physicians and surgeons in numerous countries throughout the world is predicted to hinder the adoption of GTD oncology treatments in their medical systems. The objective of the report is to present a comprehensive analysis of the Gestational Trophoblastic Disease market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Gestational Trophoblastic Disease market dynamics, structure by analyzing the market segments and projecting the Gestational Trophoblastic Disease market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Gestational Trophoblastic Disease market make the report investor’s guide.

Gestational Trophoblastic Disease Market Scope: Inquire before buying

Global Gestational Trophoblastic Disease Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2027
Historical Data: 2017 to 2021 Market Size in 2021: US $ 2.12 Bn.
Forecast Period 2022 to 2027 CAGR: 4.1% Market Size in 2027: US $ 2.7 Bn.
Segments Covered: by Type • Hydatidiform mole • Complete • Partial • Invasive • Choriocarcinoma • Placental-site trophoblastic tumor • Epithelioid trophoblastic tumor • Others
by Treatment • Surgery • Abdominal hysterectomy • Vaginal hysterectomy • Chemotherapy • Suction dilation and curettage (D&C) • Radiation Therapy
by End-User • Hospital and clinics • Diagnostic centers • Others

Gestational Trophoblastic Disease Market, by Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America

Gestational Trophoblastic Disease Market Key Players

Hikma Pharmaceuticals PLC • Pfizer Inc. • Bristol-Myers Squibb Company • Antares Pharma • Mylan N.V. • Novartis AG • Teva Pharmaceutical Industries Ltd. • BP Pharmaceuticals Laboratories Company • Fresenius Kabi AG • Accord Healthcare, Inc. • Eli Lilly and Company • Sanofi • Bayer AG • Amgen Inc. • Merck FAQs: 1. Which is the potential market for Gestational Trophoblastic Disease in terms of the region? Ans. North America is the potential market for Gestational Trophoblastic Disease in terms of the region. 2. What are the opportunities for new market entrants? Ans. The key opportunity in the market is that emerging economies offer promising potential in the oncology healthcare sector. 3. What is expected to drive the growth of the Gestational Trophoblastic Disease market in the forecast period? Ans. The primary driver of the market is the rising patient preference for no-invasive procedures. 4. What is the projected market size & growth rate of the Gestational Trophoblastic Disease Market? Ans. Gestational Trophoblastic Disease Market size was valued at US$ 2.12 Bn. in 2021 and the total Gestational Trophoblastic Disease revenue is expected to grow at 4.1% through 2022 to 2027, reaching nearly US$ 2.7 Bn. 5. What segments are covered in the Gestational Trophoblastic Disease Market report? Ans. The segments covered are Type, Treatment, End-User, and Region.
1. Global Gestational Trophoblastic Disease Market: Research Methodology 2. Global Gestational Trophoblastic Disease Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Gestational Trophoblastic Disease Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Gestational Trophoblastic Disease Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 3.12 COVID-19 Impact 4. Global Gestational Trophoblastic Disease Market Segmentation 4.1 Global Gestational Trophoblastic Disease Market, by Type (2022-2027) • Hydatidiform mole • Complete • Partial • Invasive • Choriocarcinoma • Placental-site trophoblastic tumor • Epithelioid trophoblastic tumor • Others 4.2 Global Gestational Trophoblastic Disease Market, by Treatment (2022-2027) • Surgery • Abdominal hysterectomy • Vaginal hysterectomy • Chemotherapy • Suction dilation and curettage (D&C) • Radiation Therapy 4.3 Global Gestational Trophoblastic Disease Market, by End-User (2022-2027) • Hospital and clinics • Diagnostic centers • Others 5. North America Gestational Trophoblastic Disease Market(2022-2027) 5.1 Global Gestational Trophoblastic Disease Market, by Type (2022-2027) • Hydatidiform mole • Complete • Partial • Invasive • Choriocarcinoma • Placental-site trophoblastic tumor • Epithelioid trophoblastic tumor • Others 5.2 Global Gestational Trophoblastic Disease Market, by Treatment (2022-2027) • Surgery • Abdominal hysterectomy • Vaginal hysterectomy • Chemotherapy • Suction dilation and curettage (D&C) • Radiation Therapy 5.3 Global Gestational Trophoblastic Disease Market, by End-User (2022-2027) • Hospital and clinics • Diagnostic centers • Others 5.4 North America Gestational Trophoblastic Disease Market, by Country (2022-2027) • United States • Canada • Mexico 6. Asia Pacific Gestational Trophoblastic Disease Market (2022-2027) 6.1. Asia Pacific Gestational Trophoblastic Disease Market, by Type (2022-2027) 6.2. Asia Pacific Gestational Trophoblastic Disease Market, by Treatment (2022-2027) 6.3. Asia Pacific Gestational Trophoblastic Disease Market, by End-User (2022-2027) 6.4. Asia Pacific Gestational Trophoblastic Disease Market, by Country (2022-2027) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 7. Middle East and Africa Gestational Trophoblastic Disease Market (2022-2027) 7.1 Middle East and Africa Gestational Trophoblastic Disease Market, by Type (2022-2027) 7.2. Middle East and Africa Gestational Trophoblastic Disease Market, by Treatment (2022-2027) 7.3. Middle East and Africa Gestational Trophoblastic Disease Market, by End-User (2022-2027) 7.4. Middle East and Africa Gestational Trophoblastic Disease Market, by Country (2022-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 8. Latin America Gestational Trophoblastic Disease Market (2022-2027) 8.1. Latin America Gestational Trophoblastic Disease Market, by Type (2022-2027) 8.2. Latin America Gestational Trophoblastic Disease Market, by Treatment (2022-2027) 8.3. Latin America Gestational Trophoblastic Disease Market, by End-User (2022-2027) 8.4 Latin America Gestational Trophoblastic Disease Market, by Country (2022-2027) • Brazil • Argentina • Rest Of Latin America 9. European Gestational Trophoblastic Disease Market (2022-2027) 9.1. European Gestational Trophoblastic Disease Market, by Type (2022-2027) 9.2. European Gestational Trophoblastic Disease Market, by Treatment (2022-2027) 9.3. European Gestational Trophoblastic Disease Market, by End-User (2022-2027) 9.4. European Gestational Trophoblastic Disease Market, by Country (2022-2027) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 10. Company Profile: Key players 10.1 Hikma Pharmaceuticals PLC 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2 Pfizer Inc. 10.3 Bristol-Myers Squibb Company 10.4 Antares Pharma 10.5 Mylan N.V. 10.6 Novartis AG 10.7 Teva Pharmaceutical Industries Ltd. 10.8 BP Pharmaceuticals Laboratories Company 10.9 Fresenius Kabi AG 10.10 Accord Healthcare, Inc. 10.11 Eli Lilly and Company 10.12 Sanofi 10.13 Bayer AG 10.14 Amgen Inc. 10.15 Merck

About This Report

Report ID 66040
Category Healthcare
Published Date July 2020
Updated Date March 2022
Contact Us